MBK Partners to acquire Alinamin Pharmaceutical from Blackstone for $2.1bn.

MBK Partners, a private equity firm, agreed to acquire Alinamin Pharmaceutical, a pharmaceutical company, from Blackstone, an American alternative investment management company, for $2.1bn. MBK Partners' acquisition of Alinamin represents the Korean equity firm's strategy to strengthen its health care business. It has recently taken over South Korea's leading dental implant firm Osstem Implant and 3D dental scanner maker Medit Corp.